Currently, there are 385.00M common shares owned by the public and among those 343.19M shares have been available to trade.
The company’s stock has a 5-day price change of -12.24% and -33.21% over the past three months. MRNA shares are trading -12.10% year to date (YTD), with the 12-month market performance down to -63.83% lower. It has a 12-month low price of $31.94 and touched a high of $170.47 over the same period. MRNA has an average intraday trading volume of 10.33 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -7.75%, -10.06%, and -55.65% respectively.
Institutional ownership of Moderna Inc (NASDAQ: MRNA) shares accounts for 66.29% of the company’s 385.00M shares outstanding.
It has a market capitalization of $14.07B and a beta (3y monthly) value of 1.59. The earnings-per-share (ttm) stands at -$5.82. Price movements for the stock have been influenced by the stock’s volatility, which stands at 8.10% over the week and 8.16% over the month.
Earnings per share for the fiscal year are expected to increase by 25.90%, and 1.55% over the next financial year. EPS should grow at an annualized rate of 16.86% over the next five years, compared to -20.02% over the past 5-year period.
Looking at the support for the MRNA, a number of firms have released research notes about the stock. Goldman stated their Neutral rating for the stock in a research note on January 29, 2025, with the firm’s price target at $99-$51. BofA Securities was of a view on December 10, 2024 that the stock is Underperform, while Berenberg gave the stock Hold rating on November 19, 2024, issuing a price target of $42. HSBC Securities on their part issued Buy rating on November 18, 2024.
